Exploiting CDA-Mediated metabolism of 5fdC to overcome cytarabine resistance in Malignant myeloid cells leukemia
Biochemical Pharmacology · 2026-09 · 251 · 118064
DOI: 10.1016/j.bcp.2026.118064 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical Pharmacology, 2026-09. Verfasst von Anran Fan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Tissue Engineering and Stem Cell Research, Key Laboratory of Functional Nucleic Acids-Based Biopharmaceutical Research, Guizhou Biomanufac…. Hauptthemen laut MEDLINE: Cytarabine, Drug Resistance, Neoplasm, Cytidine Deaminase, Antimetabolites, Antineoplastic. Die Arbeit nennt 43 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Department of Education of Guizhou Province.
Abstract (Originalsprache)
Myeloid leukemia (ML) remains a therapeutic challenge due to the frequent development of resistance to frontline cytosine arabinoside (AraC). One of a key driver of this resistance is the overexpression of cytidine deaminase (CDA), which inactivates AraC. Here, we present a counterintuitive therapeutic strategy that exploits this very resistance pathway to overcome chemoresistance. We demonstrate that the 5-formyl-2'-deoxycytidine (5fdC) is activated by CDA into the cytotoxic metabolite 5-formyl-2'-deoxyuridine (5fdU) in AraC resistant leukemia cells. This CDA mediated metabolism, which undermines AraC therapy, becomes a critical vulnerability for resistant cells. In both in vitro AraC resistant cell lines and CDA overexpressing animal models, the conversion of 5fdC to 5fdU potently induces DNA damage and triggers apoptosis. Consequently, 5fdC exhibits enhanced and selective cytotoxicity specifically against AraC resistant leukemia cells, while showing comparatively less effect on sensitive cells. Our work unveils a novel metabolic targeting approach, turning a key resistance mechanism into a therapeutic Achilles' heel for treating refractory myeloid leukemia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Tissue Engineering and Stem Cell Research, Key Laboratory of Functional Nucleic Acids-Based Biopharmaceutical Research, Guizhou Biomanufacturing Laboratory, Guizhou Medical University, Guiyang, China; Key Lab…
Förderung
- National Natural Science Foundation of China
- Department of Education of Guizhou Province
Zitieren
APA
Fan, A., Dong, M., Fan, N., Luo, Q., Mo, J., Ai, L., Zhou, Y., & Zhang, P. (2026). Exploiting CDA-Mediated metabolism of 5fdC to overcome cytarabine resistance in Malignant myeloid cells leukemia. Biochemical Pharmacology, 251, 118064. https://doi.org/10.1016/j.bcp.2026.118064
Vancouver
Fan A, Dong M, Fan N, Luo Q, Mo J, Ai L, et al. Exploiting CDA-Mediated metabolism of 5fdC to overcome cytarabine resistance in Malignant myeloid cells leukemia. Biochemical Pharmacology. 2026;251:118064. doi:10.1016/j.bcp.2026.118064
BibTeX
@article{Fan2026,
author = {Fan, Anran and Dong, Meiling and Fan, Nanying and Luo, Qingyuan and Mo, Jun and Ai, Lili and Zhou, Yanhua and Zhang, Peng},
title = {Exploiting CDA-Mediated metabolism of 5fdC to overcome cytarabine resistance in Malignant myeloid cells leukemia},
journal = {Biochemical Pharmacology},
year = {2026},
volume = {251},
pages = {118064},
doi = {10.1016/j.bcp.2026.118064}
}
EUVIMED